drugset / Trial / NCT01297920
Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study was to evaluate the safety and efficacy of a new ophthalmic suspension (Brinz/Brim) in lowering intraocular pressure (IOP) relative to its individual active components in subjects with open-angle glaucoma and/or ocular hypertension.
Timeline
- Start
- 2011-03
- Primary completion
- 2012-06
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brimonidine | Small molecule | 0.2 % | Topical |
| Subject | Brinzolamide | Small molecule | 1 % | Topical |